Low-cost antidepressant found to reduce long COVID fatigue in study

A new study suggests that fluvoxamine, a common and inexpensive antidepressant, may help ease the crushing fatigue that often comes with long COVID. Researchers enrolled 399 adults with long COVID symptoms and gave half of them fluvoxamine and the other half a placebo. The results showed that those taking the drug reported significantly less fatigue and better overall quality of life. This is one of the first medications to show clear benefits for long COVID fatigue, a condition that can last for months and interfere with daily activities. Fluvoxamine belongs to a class of drugs called SSRIs, which are typically used to treat depression and anxiety. The study's lead researcher noted that while the findings are promising, more research is needed to confirm the drug's effectiveness and understand exactly how it works. The trial was randomized and place-controlled, meaning it is considered a reliable form of evidence. Long COVID affects millions worldwide, and symptoms vary widely. Fatigue is one of the most common and disabling complaints, often persisting after other symptoms have resolved. If confirmed, fluvoxamine could offer an affordable treatment option for those struggling with this debilitating symptom.